Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for pediatric and other cancers, including solid tumors. The company's mission is to provide innovative treatments that address unmet medical needs in oncology. Salarius is dedicated to advancing its lead candidate, Seclidemstat, which targets various forms of cancer. The firm primarily serves patients in the United States, aiming to improve outcomes and quality of life for those affected by these serious conditions.

Salarius Pharmaceuticals has achieved significant milestones, including presenting clinical data on Seclidemstat at the European Hematology Association Annual Meeting and receiving clearance to begin a Phase I trial for SP-2577 in non-Hodgkin lymphoma. These advancements underscore the company's commitment to pioneering cancer therapies. Salarius continues to participate in key industry events, such as the Annual Tumor Models Conference, further establishing its presence in the oncology research community.